The day-to-day practice of MMR and MSI assessment in colorectal adenocarcinoma: what we know and what we still need to explore.

BACKGROUND: The DNA Mismatch repair (MMR) system is a highly preserved protein complex recognizing short insertions, short deletions and single base mismatches during DNA replication and recombination. MMR protein status is identified using immunohistochemistry (IHC). Deficit in one or more MMR proteins, configuring deficient MMR status (dMMR), leads to frameshift mutations particularly clustered in microsatellite repeats. Thus, microsatellite instability (MSI) is the epiphenomenon of dMMR. In colorectal cancer (CRC), MMR/MSI status is a biomarker with prognostic and predictive value of resistance to 5-fluorouracil and response to immune checkpoint inhibitor (ICI) therapy.

SUMMARY: In this Review, we describe the challenges the practicing pathologist may face in relation to the assessment of MMR/MSI status and any open issues which still need to be addressed, focusing on pre-analytic issues, pitfalls in the interpretation and technical aspects of the different assays.

KEY MESSAGES: The current methods of detecting dMMR /MSI status have been optimized for CRCs, and whether these techniques can be applied in all tumor and specimen types are still not fully understood. Following the Food and Drug Administration (FDA), tissue/site agnostic drug approval of pembrolizumab for advanced/metastatic MSI tumors, MMR/MSI status in Gastro-Intestinal (GI) tract is a common request from the oncologist. In this setting, several issues still need to be addressed, including criteria for sample adequacy.